Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives

Biocon Biologics Ltd. (BBL) has secured multiple market access agreements for Yesintek™ (ustekinumab-kfce), its biosimilar to Stelara® (ustekinumab), covering over 100+ million lives in the United States. Express Scripts, Cigna, UnitedHealthcare, CVS Health, and Optum Rx have added Yesintek™ to their formularies. Yesintek™ is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. It is available in all the same formulations currently provided by Stelara®. Clinical studies have shown that Yesintek™ is a biosimilar to Stelara® with similar pharmacokinetic, safety, efficacy, and immunogenicity profiles. Yesintek™ received U.S. Food and Drug Administration (FDA) approval in December 2024.